retatrutide triple hormone receptor agonist obesity is a triple-agonist drug targeting GLP-1, GIP, and glucagon receptors to suppress appetite and boost thermogenesis. Phase 2 trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Phase 2 Trial of Retatrutide

284 Emerging epigenetic data suggest that GLP-1 RAs may decelerate biological aging via DNA methylation modifications at loci associated with inflammatory and metabolic regulation, consistent with observed reductions in biological age

Frequent monitoring and insulin down-titration are advised if the patient continues with a corticosteroid for Covid-19 following discharge from hospital

L-Carnitine plays a role in transporting fatty acids within the body, where they may be utilized for energy production

For example, an individual who experiences frequent reflux might find that the delayed gastric emptying of a GLP-1 medication temporarily worsens their symptoms